Bristol Myers Squibb raises quarterly dividend and adds $15 billion to share buyback programMarket Watch • 12/13/21
Bristol Myers Squibb Announces Dividend Increase and Additional $15 Billion Share Repurchase AuthorizationBusiness Wire • 12/13/21
Bristol Myers Squibb's Breyanzi (lisocabtagene maraleucel) Significantly Improves Outcomes, Showing Superiority Over 20-Year Standard of Care in Second-Line Relapsed or Refractory Large B-cell Lymphoma Based on TRANSFORM Study ResultsBusiness Wire • 12/11/21
Could Bristol Myers Squibb and Johnson & Johnson Have a Powerful New Blood Thinner on the Way?The Motley Fool • 12/04/21
U.S. Food and Drug Administration Accepts for Priority Review supplemental Biologics License Application for Reblozyl® (luspatercept-aamt) in Adults with Non-Transfusion Dependent (NTD) Beta ThalassemiaBusiness Wire • 12/03/21
High Doses Of Dividend Growth Expected From Pfizer, Eli Lilly, Bristol Myers In DecemberSeeking Alpha • 11/29/21